Elimusertib

Elimusertib (Bay 1895344) is an experimental anticancer drug which acts as an inhibitor of ataxia telangiectasia and Rad3 related protein. This is involved in DNA repair following damage, and so inhibiting this protein causes cancer cells to become more vulnerable to other chemotherapy drugs. Elimusertib is in early stage clinical trials against advanced solid tumors.^[1][2][3][4]

Elimusertib

Identifiers
IUPAC name (3R)-3-methyl-4-[4-(2-methylpyrazol-3-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-2-yl]morpholine
CAS Number	1876467-74-1
PubChem CID	118869362
IUPHAR/BPS	10354
DrugBank	DB19041
ChemSpider	64854199
UNII	7N13IK9LNH
ChEMBL	ChEMBL4647810
Chemical and physical data
Formula	C20H21N7O
Molar mass	375.436 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@@H]1COCCN1C2=NC3=C(C=CN=C3C4=CC=NN4)C(=C2)C5=CC=NN5C
InChI InChI=1S/C20H21N7O/c1-13-12-28-10-9-27(13)18-11-15(17-5-8-23-26(17)2)14-3-6-21-20(19(14)24-18)16-4-7-22-25-16/h3-8,11,13H,9-10,12H2,1-2H3,(H,22,25)/t13-/m1/s1 Key:YBXRSCXGRPSTMW-CYBMUJFWSA-N